MedPath

AKI Prevention and Early Intervention in Patients Undergoing VAD Placement

Not Applicable
Completed
Conditions
Kidney Injury
Interventions
Other: Clinical Recommendations
Registration Number
NCT03236831
Lead Sponsor
Mayo Clinic
Brief Summary

The investigators are doing this research to find out if more careful assessment and elimination of potential risk factors of acute kidney injury (AKI) during the subject's perioperative period will reduce their chance of kidney damage and kidney damage related problems.

Detailed Description

The purpose of the study is to investigate whether preventive measures for patients undergoing ventricular assist device (VAD) placement will reduce AKI occurrence, progression and associated complications.

Participants will be in the study for a total of 6 days (1 day prior to the surgery and 5 days after the surgery). The investigators will review the participant's medical record up to one year after surgery.

The study investigators will access the participant's electronic medical record 24 hours prior to the planned VAD implantation and review the participant's medication regimen and provide recommendations to the participant's primary care physician in an effort to minimize potential risks for AKI. There will be no intervention during the operation.

The clinical recommendations will cover the following:

1. Avoidance of potentially nephrotoxic agents.

2. Optimizing volume status (avoidance of volume overload or depletion)

3. Optimizing electrolytes and acid-base status

4. Minimizing IV contrast exposure when appropriate

5. Treating severe anemia

6. Optimization of hemodynamics (Mean arterial BP\>65mmHg).

The investigators plan to compare the results of this study with the historical data in the same patient population in the years of 7/1/2015-6/30/2017.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
210
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Subjects Undergoing Prospective VADClinical RecommendationsPatients undergoing VAD placement. The investigators will provide clinical recommendations to the subject's primary care provider.
Primary Outcome Measures
NameTimeMethod
Rate of postoperative AKI (within 5 post-op days) based on AKIN criteria5 days after the surgery

The Acute Kidney Injury Network (AKIN) staging system has 3 stages: 1) serum creatinine increase ≥ 26.5 umol/L or increase to 1.5-2.0 fold from baseline, OR urine output \<0.5 ml/kg/h for 6 h; 2) serum creatinine increase \> 2.0-3.0 fold from baseline OR urine output \<0.5 ml/kg/h for 12 h; 3) serum creatinine increase \>3.0 fold from baseline OR serum creatinine ≥354 umol/l with an acute increase of at least 44 umol/l or need for Renal Replacement Therapy (RRT) OR urine output \<0.3 ml/kg/h for 24 h OR anuria for 12 OR need for RRT

Secondary Outcome Measures
NameTimeMethod
Severity of postoperative AKI (within 5 post-op days) based on AKIN criteria5 days after the surgery

The AKIN staging system has 3 stages: 1) serum creatinine increase ≥ 26.5 umol/L or increase to 1.5-2.0 fold from baseline, OR urine output \<0.5 ml/kg/h for 6 h; 2) serum creatinine increase \> 2.0-3.0 fold from baseline OR urine output \<0.5 ml/kg/h for 12 h; 3) serum creatinine increase \>3.0 fold from baseline OR serum creatinine ≥354 umol/l with an acute increase of at least 44 umol/l or need for Renal Replacement Therapy (RRT) OR urine output \<0.3 ml/kg/h for 24 h OR anuria for 12 OR need for RRT

Length of hospital stay1 year after the surgery

The length of hospital stay will be determined from the electronic medical record.

In hospital (perioperative) mortality and one-year mortalityApproximately 5 days after surgery, one year after enrollment

The number of subjects who died in hospital (perioperatively) and one year after surgery

Trial Locations

Locations (1)

Mayo Clinic in Rochester

🇺🇸

Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath